Dual-time-point FDG-PET/CT for the detection of hepatic metastases

被引:79
作者
Dirisamer, Albert [1 ,3 ]
Halpern, Benjamin S. [1 ]
Schima, Wolfgang [1 ]
Heinisch, Martin [2 ,3 ]
Wolf, Florian [1 ]
Beheshti, Mohsen [3 ]
Dirisamer, Franz [4 ]
Weber, Michael [1 ]
Langsteger, Werner [3 ]
机构
[1] Univ Hosp Vienna, Vienna, Austria
[2] Hosp Wels, Wels, Austria
[3] St Vincents Hosp, Dept Nucl Med, PET CT Ctr, Linz, Austria
[4] Gen Hosp Linz, Linz, Austria
关键词
dual time point; FDG PET; liver metastasis;
D O I
10.1007/s11307-008-0159-y
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose: To prove the sensitivity of dual-time-point imaging with 18F-flourodeoxyglucose-positron emission tomography (18F-FDG-PET) of the liver to evaluate possible changes in the tumor-to-background ratio considering an improved detection rate of liver lesions. Procedures: Image acquisition for the first whole-body scan started at a mean time point of 69 min (55-110 min). The mean time interval between the injection of 18F-FDG and the second delayed scan was 100 min (85-166 min). Results: Of 90 proven liver metastases in 34 patients, the first scan detected 53 (59%) liver lesions correctly, whereas in the second, delayed scan 81 (90%) lesions were diagnosed correctly (p < 0.001). The mean Standardized uptake values in the first and second delayed scan were 6.59 g/ml versus 8.09 g/ml, respectively (p < 0.001). Tumor-to-background ratio of the first and second delayed scan were 2.0 and 2.7, respectively (p = 0.04). Conclusions: Dual-time-point-imaging of the liver showed a significant increase of tumor-to-background ratio and hypermetabolic lesion diameter. Although, 30% of all verified liver lesions could only be detected in the second delayed scan 10% of all malignant liver lesions were missed with FDG-PET.
引用
收藏
页码:335 / 340
页数:6
相关论文
共 30 条
[1]  
*AM CANC SOC, 1999, CANC FACTS FIG 1999
[2]  
Beaulieu S, 2003, J NUCL MED, V44, P1044
[3]  
Brix G, 2001, J NUCL MED, V42, P1265
[4]   Narrow time-window dual-point 18F-FDG PET for the diagnosis of thoracic malignancy [J].
Conrad, GR ;
Sinha, P .
NUCLEAR MEDICINE COMMUNICATIONS, 2003, 24 (11) :1129-1137
[5]   Normal variants, artefacts and interpretative pitfalls in PET imaging with 18-fluoro-2-deoxyglucose and carbon-11 methionine [J].
Cook, GJR ;
Maisey, MN ;
Fogelman, I .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 1999, 26 (10) :1363-1378
[6]  
HAMBERG LM, 1994, J NUCL MED, V35, P1308
[7]   Differentiating benign from malignant lung lesions using ''quantitative'' parameters of FDG PET images [J].
Hubner, KF ;
Buonocore, E ;
Gould, HR ;
Thie, J ;
Smith, GT ;
Stephens, S ;
Dickey, J .
CLINICAL NUCLEAR MEDICINE, 1996, 21 (12) :941-949
[8]  
Huebner RH, 2000, J NUCL MED, V41, P1177
[9]   Can the standardized uptake value characterize primary brain tumors on FDG-PET? [J].
Hustinx, R ;
Smith, RJ ;
Benard, F ;
Bhatnagar, A ;
Alavi, A .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 1999, 26 (11) :1501-1509
[10]   FLUORODEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY IN PANCREATIC-CANCER - AN UNSOLVED PROBLEM [J].
KATO, T ;
FUKATSU, H ;
ITO, K ;
TADOKORO, M ;
OTA, T ;
IKEDA, M ;
ISOMURA, T ;
ITO, S ;
NISHINO, M ;
ISHIGAKI, T .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 1995, 22 (01) :32-39